Study finds sarcoidosis may follow 2 distinct paths after diagnosis
Early treatment and clinic of diagnosis helped predict a chronic disease course
Written by |
Sarcoidosis appears to follow two main trajectories, and clinical and treatment features at diagnosis may help predict whether the disease will resolve within the first few years or persist, according to a large study in Sweden involving more than 9,000 adult patients.
About seven in 10 patients had few to no sarcoidosis-related healthcare visits within two years of diagnosis, a pattern consistent with resolving disease. Nearly three in 10 continued to have frequent sarcoidosis-related healthcare visits throughout the five-year study, a pattern consistent with a chronic disease trajectory.
Early organ involvement may signal a chronic disease course
Possible involvement of the eyes, nervous system, or heart at diagnosis was associated with a greater likelihood of persistent disease, while receiving immunosuppressive treatment within three months before or after diagnosis was the strongest predictor of chronic disease.
People with a chronic disease trajectory had higher risks of infections, heart failure, diabetes, depression, anxiety, and early death. The findings highlight that “early prognostication [prediction]” of the disease course “may support personalized sarcoidosis management,” the researchers wrote.
The study, “Sarcoidosis data-driven patient trajectories and predictors of chronic disease,” was published in Respiratory Research.
Sarcoidosis occurs when an overactive immune response causes clusters of inflammatory cells, called granulomas, to form in organs throughout the body, leading to a wide range of symptoms. The lungs are affected in about 90% of cases, but the disease also can involve the skin, eyes, heart, and nervous system.
Some people develop Löfgren syndrome, an acute form of sarcoidosis that usually resolves on its own within two years. In others, the disease persists and may progressively impair organ function or contribute to early death.
Yet “no single sarcoidosis-related factor or biomarker can accurately prognosticate the course of disease at diagnosis,” the researchers wrote.
To better understand how sarcoidosis progresses over time and what might predict its course at diagnosis, researchers at the Karolinska Institutet in Sweden analyzed data from 9,665 adults newly diagnosed with sarcoidosis from 2006 through 2018.
Swedish registry data reveal two long-term sarcoidosis patterns
The study drew data from the Swedish National Patient Register, which records healthcare visits nationwide. Participants had a mean age of 50.4 years at diagnosis, and 43.2% were women.
About four in 10 received immunosuppressive treatment around diagnosis, while 26% were prescribed nonsteroidal anti-inflammatory drugs (NSAIDs), a different class of medication from corticosteroids — the first-line treatment for sarcoidosis.
The team tracked sarcoidosis-related hospital and specialist visits for five years, looking for common patterns in how healthcare use changed over time. They then examined whether features present at diagnosis could predict these disease patterns and whether the trajectories were linked to long-term complications.
Two clear patterns emerged. Most participants (71.5%) followed a resolving course, with sarcoidosis-related visits dropping rapidly to nearly zero within two years. The other 28.5% followed a chronic course, with frequent visits continuing throughout the five years and averaging about 1.5 every six months after the second year.
The specialty of the clinic where patients were first diagnosed — an approximate indicator of the main disease manifestation at diagnosis — was a strong predictor of disease course.
Compared with patients in the study’s “Other” clinic category, those first diagnosed in neurology or ophthalmology clinics had a significantly higher risk — by more than 50% — of following a chronic course.
Compared with the same group, being first diagnosed in a cardiology clinic was associated with a 23% higher risk of following a chronic course.
Treatment need was strongest predictor of chronic disease
In contrast, people first diagnosed in rheumatology clinics, which focus on inflammatory diseases affecting the joints, muscles, bones, and connective tissues, had a significantly lower risk — by 35% — of following a chronic course.
Receiving immunosuppressive treatment, such as corticosteroids, within three months before or after diagnosis was the strongest predictor of a chronic course. Such treatment, which may reflect more severe disease requiring early treatment, was associated with more than twice the risk of chronic disease.
In contrast, people prescribed NSAIDs within six months before diagnosis, which may reflect a more acute disease presentation, were 24% less likely to follow a chronic course.
Moreover, patients with a chronic disease trajectory had significantly poorer long-term outcomes, with rates of infection, heart failure, diabetes, depression, anxiety, and death from any cause about 1.5 to two times as high.
“These findings underscore the value of early clinical and treatment markers in predicting long-term outcomes and highlight the need for future studies integrating genetic and molecular data to improve personalized prognosis and management of sarcoidosis,” the researchers wrote.
Leave a comment
Fill in the required fields to post. Your email address will not be published.